Alfuzosin Hcl

證據等級: L5

預測適應症: 0 個

Alfuzosin HCL: Repurposing Evaluation — Insufficient Data to Proceed

One-Sentence Summary

Alfuzosin HCL is an alpha-1 adrenergic receptor antagonist, recognised in published literature as a treatment for the symptomatic management of benign prostatic hyperplasia (BPH). No TxGNN repurposing predictions are currently available for this drug, and the dataset contains no MHRA marketing authorisation records. A substantive repurposing evaluation cannot be completed until the identified data gaps are resolved.

Quick Overview

Item	Content
Original Indication	Not available in current dataset
Predicted New Indication	No predictions available
TxGNN Prediction Score	Not available
Evidence Level	L5 — pipeline not yet executed for this drug
UK Market Status	Not marketed (per current dataset)
Number of Marketing Authorisations	0
Recommended Decision	Hold

Background: What Is Alfuzosin HCL?

Although detailed mechanism of action data is not available in the current Evidence Pack, Alfuzosin HCL is a selective alpha-1 adrenergic receptor antagonist. It acts by relaxing smooth muscle in the prostate and bladder neck, thereby reducing urinary outflow obstruction associated with BPH. It belongs to the same pharmacological class as tamsulosin and doxazosin.

No TxGNN repurposing predictions have been generated for this drug in the current run. The predicted_indications array is empty, which indicates either that the prediction pipeline has not yet been executed for Alfuzosin HCL, or that the DrugBank ID mapping failed upstream (as confirmed by the null DrugBank ID in the Evidence Pack). Until the drug is correctly mapped in the knowledge graph, no mechanistic or clinical reasoning about potential new indications can be performed.

Clinical Trial Evidence

Currently no related clinical trials registered for a repurposing indication.

Literature Evidence

Currently no related literature available for a repurposing indication.

UK Market Information

No MHRA marketing authorisations are recorded in the current dataset for Alfuzosin HCL.

Note for reviewers: Alfuzosin-based products (e.g., Xatral® XL) have historically been available in the UK market. The absence of authorisation records here is likely a data pipeline gap rather than a true absence of UK authorisation. MHRA Product Licence data should be retrieved directly from the MHRA Product Information database and the BNF (Section 7.4.1: Drugs used in urological pain) before drawing any regulatory conclusions.

Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack contains no TxGNN predictions and no MHRA authorisation records for Alfuzosin HCL; without a resolved DrugBank ID and completed prediction pipeline, there is no repurposing candidate to evaluate at this stage.

To proceed, the following is needed:

Resolve DrugBank ID mapping — the drugbank_id field is null; query the DrugBank API for Alfuzosin HCL (also try “alfuzosin”) to obtain the correct ID (expected: DB00346), then re-run the TxGNN prediction pipeline
Re-execute TxGNN predictions — once the DrugBank ID is confirmed, rerun scripts/run_kg_prediction.py to populate predicted_indications
Retrieve MHRA authorisation data — query the MHRA Product Licences database for all PL numbers associated with alfuzosin; cross-reference with BNF 7.4.1 and NICE guidance
Obtain SmPC safety data — download the current Summary of Product Characteristics from the MHRA electronic medicines compendium (emc) to populate warnings, contraindications, and drug interactions
Retrieve MOA data — query DrugBank once the ID is resolved to confirm receptor selectivity profile, which is needed for mechanism-based repurposing rationale
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.